Physician profile
Holly On
NPI 1669153151
$6,670.24
in general payments reported to CMS, 2019-2025
47 companies · $3,922 in 2025
The $3,922 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $479 · 2024: $2,269 · 2025: $3,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,285 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,285.05 |
| Education | $385.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,230.55 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Novartis Pharmaceuticals Corporation | $464.32 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $401.83 | 2023-2025 | Calquence, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $392.92 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $316.10 | 2023-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $293.45 | 2023-2025 | Livtencity, Fruzaqla, Alunbrig |
| Daiichi Sankyo INC. | $285.82 | 2024-2025 | Enhertu, Datroway |
| Incyte Corporation | $268.54 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Glaxosmithkline, LLC. | $267.28 | 2024-2025 | Ojjaara, Blenrep, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $237.34 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $222.18 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Lilly USA, LLC | $201.37 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $150.31 | 2023-2025 | |
| Abbvie INC. | $149.76 | 2024-2025 | |
| Astellas Pharma US INC | $147.89 | 2024-2025 | Vyloy, Xtandi, Xospata |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $122.87 | 2023-2025 | |
| Tersera Therapeutics LLC | $117.26 | 2025 | Zoladex |
| Celgene Corporation | $114.86 | 2025 | Reblozyl |
| Geron Corporation | $109.22 | 2025 | Rytelo |
| Legend Biotech USA INC. | $103.92 | 2025 | Carvykti |
| Pfizer INC. | $86.98 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $80.29 | 2024-2025 | Orgovyx |
| Gilead Sciences, INC. | $79.67 | 2024-2025 | Trodelvy |
| Seagen INC. | $73.99 | 2025 | |
| Alexion Pharmaceuticals, INC. | $63.44 | 2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $50.55 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $48.90 | 2024-2025 | Pyrukynd |
| Kite Pharma, INC. | $48.88 | 2025 | Yescarta |
| Eisai INC. | $45.13 | 2024 | |
| Aveo Pharmaceuticals, INC. | $44.23 | 2023-2025 | Fotivda |
| Puma Biotechnology, INC. | $44.00 | 2024-2025 | |
| Array Biopharma INC | $43.05 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Ipsen Biopharmaceuticals, INC | $42.37 | 2025 | Onivyde, Somatuline Depot |
| Mirati Therapeutics, INC. | $40.68 | 2024 | Krazati |
| Sobi, INC | $36.35 | 2024 | |
| Emd Serono, INC. | $32.24 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $28.68 | 2025 | Clonoseq |
| Immunocore Limited | $27.11 | 2025 | Kimmtrak |
| Dendreon Pharmaceuticals LLC | $22.56 | 2023 | Provenge |
| Pharmacosmos Therapeutics INC. | $22.06 | 2024 | Cosela |
| Stemline Therapeutics INC. | $21.11 | 2024 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.88 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.17 | 2024 | Xarelto |
| Blueprint Medicines Corporation | $14.99 | 2023 | Ayvakit |
| Genentech USA, INC. | $14.54 | 2023 | Perjeta, Phesgo, Kadcyla |
| Servier Pharmaceuticals LLC | $13.50 | 2024 | |
| Genmab U.S., INC. | $13.10 | 2024 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly On listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.